Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer

摘要

The pemetrexed-resistant PC-9 cell line acquired EGFR-TKI resistance. - Viabilities of the human EGFR-mutant NSCLC cell line PC-9 and the PEM-resistant cell line PC-9/PEM treated for 72 h with pemetrexed or EGFR-TKI at the indicated concentrations. Data are means (SD),  = 3. *,  P P P t-test